Journal international de neuroréadaptation

Transcranial Pulse Stimulation Retrospective Real-World Pilot Data in Patients with Mild to Severe Alzheimers

Abstract

Celine Cont

Introduction: A non-invasive form of neuromodulation known as transcranial pulse stimulation (TPS) makes use of a neuro-navigated device to deliver brief, recurrent shockwaves. These pulses may cause a wide range of vascular, metabolic, and neurotrophic changes, according to current research. In a clinical pilot study for improving cognition in mild-to-moderate Alzheimer's, this relatively new CE-marked treatment produced its first promising results. Because there is a lack of data from other centers, we examined the safety and pilot real-world short-term TPS results from the first center in Germany. To acquire data about impacts in various stages, patients with gentle as well as moderate-to-extreme Alzheimer's were examined.

Methods: Before and after the first stimulation series, 11 patients were examined for cognitive and emotional function in a retrospective manner. The impact was surveyed utilizing a few neuropsychological tests [Alzheimer's Illness Evaluation Scale (ADAS), including the ADAS mental score (ADAS Pinion) and ADAS emotional scores, Smaller than expected Mental Status Assessment (MMSE), and Montreal Mental Evaluation (MoCA)] remembering for examination between the gatherings of gentle to-extreme patients. Numeric Rating Scales (NRS) were also used to examine subjective improvement in symptom severity, potential effects on depressive symptoms, and side effects.

Results: In only 4% of sessions, side effects occurred that were only brief and of moderate subjective severity. Patients fundamentally worked on in the ADAS and ADAS Pinion, while there was no massive impact in MMSE and MoCA. The self-reported severity of symptoms significantly improved among patients. Also significantly improved were the ADAS subscale measures of depressive symptoms. There was no significant correlation between clinical improvement and baseline symptom severity, according to statistical data analyses.

Conclusion: TPS may be a protected and promising extra treatment for Alzheimer's, in any event, for moderate-to-serious patients. More studies with sham control groups and long-term effects on patients are needed. In addition, in order to comprehend this novel method of neuromodulation, translational research on the mechanisms of action and effects on the physiology of cerebral networks will be required.